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ABSTRACT: Introduction: Eculizumab is effective and well tolerated
in patients with antiacetylcholine receptor antibody-positive refractory
generalized myasthenia gravis (gMG; REGAIN; NCT01997229). We
report an interim analysis of an open-label extension of REGAIN,
evaluating eculizumab’s long-term safety and efﬁcacy. Methods:
Eculizumab (1,200 mg every 2 weeks for 22.7 months [median])
was administered to 117 patients. Results: The safety proﬁle of
eculizumab was consistent with REGAIN; no cases of meningo-
coccal infection were reported during the interim analysis period.
Myasthenia gravis exacerbation rate was reduced by 75% from
the year before REGAIN (P < 0.0001). Improvements with eculi-
zumab in activities of daily living, muscle strength, functional abil-
ity, and quality of life in REGAIN were maintained through
3 years; 56% of patients achieved minimal manifestations or
pharmacological remission. Patients who had received placebo
during REGAIN experienced rapid and sustained improvements
during open-label eculizumab (P < 0.0001). Discussion: These
ﬁndings provide evidence for the long-term safety and sustained
efﬁcacy of eculizumab for refractory gMG.
Muscle Nerve 000: 000–000, 2019
Generalized myasthenia gravis (gMG) is a chronic,
rare autoimmune disorder that is characterized by
severe muscle weakness.1 Autoantibodies to the acetyl-
choline receptor are present in 73%–88% of patients
with gMG.2–7 These autoantibodies initiate accelerated
endocytosis and degradation of acetylcholine receptors
and complement-mediated destruction of the neuro-
muscular junction, resulting in further reductions in
acetylcholine and sodium channel receptors.1,8–13 The
complement-mediated pathological membrane changes
reduce the efﬁciency of neurotransmission at the neuro-
muscular junction, resulting in the characteristic muscle
weakness and fatigability that are observed in patients
with MG.1,14
Some patients (10%–15%) with MG do not respond
adequately to long-term treatment with corticosteroids
or multiple steroid-sparing immunosuppressive thera-
pies (IST), experience intolerable side effects, or require
ongoing treatment with intravenous immunoglobulin
(IVIg) or plasma exchange.1,15–18 Persistent myasthenic
symptoms14–16,18,19 can adversely affect activities of daily
living, including breathing, talking, swallowing, walking,
and functional muscle strength as well as quality of life.15
Patients also have increased risks of myasthenic exacer-
bations and crises; an increased requirement for rescue
therapies; and more frequent inpatient hospitalizations,
intensive care unit admissions, and emergency room
visits.20,21
Eculizumab is a humanized monoclonal antibody that
speciﬁcally binds with high afﬁnity to human terminal
complement protein C5. This inhibits enzymatic cleav-
age of C5 to C5a and C5b, thereby preventing C5a-
induced chemotaxis of proinﬂammatory cells and
formation of the C5b-induced membrane attack com-
plex.22 Eculizumab was shown to have efﬁcacy and was
well tolerated in the 6-month randomized, double-blind,
placebo-controlled REGAIN study (NCT01997229), pro-
ducing clinically meaningful improvements in activities
of daily living, muscle strength, functional ability and
quality of life in patients with antiacetylcholine receptor
antibody-positive (AChR+) refractory gMG.14 Eculizumab
is approved for the treatment of adults with AChR+
gMG, in addition to paroxysmal nocturnal hemoglo-
binuria (PNH) and atypical hemolytic uremic syn-
drome (aHUS).
The open-label extension study of the phase
3 REGAIN (NCT02301624) was designed to evaluate
the long-term safety and efﬁcacy of eculizumab in
patients with AChR+ refractory gMG. Here we report
data from a preplanned interim analysis that was
based on a median duration of almost 2 years of ecu-
lizumab treatment.
MATERIALS AND METHODS
Study Design and Participants. Participants who com-
pleted the 6-month, double-blind REGAIN study could enter
this extension study. Full inclusion and exclusion criteria for
the REGAIN study have been published previously.14 In brief,
adults (aged ≥18 years) with the following were eligible for
REGAIN: conﬁrmed gMG with positive serology for acetylcho-
line receptor antibodies, an MG Activities of Daily Living (MG-
ADL) total score of 6 or higher, and failed treatment with 2 or
more ISTs or at least 1 IST with requirement for chronic IVIg
or plasma exchange therapy over the preceding 12 months.
Patients were excluded if they had a history of thymoma or
other thymic neoplasm, had undergone thymectomy in the
12 months before screening, experienced ocular-only MG
symptoms (Myasthenia Gravis Foundation of America [MGFA]
class I) or myasthenic crisis (MGFA class V) at screening, or
required treatment with IVIg or plasma exchange within the
4 weeks before randomization.14
Eligible patients who elected to continue into the open-label
extension were required to enter it within 2 weeks of complet-
ing REGAIN. The ﬁrst patient was enrolled on November
12, 2014, and the last patient was enrolled on March 4, 2016.
Participants received open-label eculizumab until it was other-
wise available to them, up to a maximum of 4 years in the exten-
sion study. The study was completed in January 2019.
All patients provided written, informed consent. Written
approval for the study protocol and all study amendments was
obtained from independent ethics committees or institutional
review boards at all participating sites. All human studies were
approved by the appropriate ethics committee and have been
performed in accordance with the ethical standard laid down
in the 1964 Declaration of Helsinki.
Dosing and Administration. Patients who received eculi-
zumab in REGAIN continued to receive eculizumab during
the open-label study (eculizumab/eculizumab group). Those
who received placebo in REGAIN started eculizumab treat-
ment when they entered the open-label study (placebo/eculi-
zumab group).
To preserve the blinded nature of REGAIN, patients who
entered the open-label study ﬁrst underwent a 4-week blinded
induction phase during which investigators, patients, and study
personnel remained blinded to all treatment assignments
(Fig. 1). During this phase, patients who had been assigned to
eculizumab in REGAIN received eculizumab 1,200 mg (4 vials)
on day 1 and week 2 and placebo (4 vials) at weeks 1 and
3. Patients who had been assigned to placebo in REGAIN
received eculizumab (900 mg, 3 vials) and placebo (one vial)
on day 1 and at weeks 1, 2, and 3 (Fig. 1). In the open-label
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maintenance phase, which started at week 4, all patients
received open-label eculizumab (1,200 mg) every 2 weeks.
Procedures. To mitigate the increased risk of meningo-
coccal infection associated with terminal inhibition of the
complement system,23 all patients in REGAIN were required
to receive Neisseria meningitidis vaccination according to local
guidelines at least 2 weeks before starting blinded study treat-
ment; if they were not vaccinated at the appropriate time,
patients received prophylactic antibiotics until 2 weeks after
vaccination. In the open-label study, patients were revacci-
nated according to local guidelines, which recommend revac-
cinating patients after 2–5 years to maintain active coverage.
Patients who entered the open-label study were on a stable
regimen of concomitant MG therapies, including ISTs that
could include but were not limited to corticosteroids, azathio-
prine, mycophenolate mofetil, methotrexate, cyclosporine,
tacrolimus, and cyclophosphamide. Adjustment of concomi-
tant MG therapies, including ISTs, was permitted at the discre-
tion of the study investigator but was not required by the study
protocol. Rescue therapy (e.g., high-dose intravenous cortico-
steroids, IVIg, or plasma exchange) was available at the discre-
tion of the study investigator for patients who experienced
disease exacerbation.
Validated MG assessments of activities of daily living, muscle
strength, functional ability, and quality of life were used to
evaluate the long-term efﬁcacy of eculizumab. These assess-
ments consisted of the MG-ADL scale,24 the Quantitative MG
scale (QMG),25 the MG Composite scale (MGC),26 and the
15-item MG Quality of Life questionnaire (MG-QOL15).27
MG-ADL, QMG, MGC, and MG-QOL15 assessments were per-
formed on day 1. MG-ADL, QMG, and MGC assessments were
performed weekly from week 1 through week 3. MG-ADL,
QMG, MGC, and MG-QOL15 assessments were then per-
formed at weeks 4, 8, 12, 16, 20, 26, 40, and 52 in year 1, every
6 months thereafter, and at each patient’s end of study visit.
These same 4 efﬁcacy measures were used in the REGAIN
study.14
Outcomes. We report an interim analysis of safety and efﬁ-
cacy data, including the occurrence of adverse events, and
changes in activities of daily living, muscle strength, functional
ability, and quality of life over time using 4 MG-speciﬁc disease
measures (data cutoff December 31, 2017).
The primary objective of this open-label study was to evalu-
ate the long-term safety of eculizumab. Safety was assessed by
incidences of adverse events, serious adverse events, study dis-
continuations due to adverse events, exacerbations, hospital
admissions, and rescue therapy administrations. Adverse
events were coded by preferred term by using the Medical Dic-
tionary for Regulatory Activities Version 20.1. The number of
patients who experienced an adverse event of special interest
(meningococcal infections, aspergillus infections, sepsis, any
serious infections, infusion-related reactions, serious cutane-
ous reactions, cardiac disorders, or angioedema) during each
3-month study period was determined. For this study, a clinical
deterioration/exacerbation was deﬁned as 1 of the following:
MG crisis, substantial symptomatic worsening (to a score of
3 or a 2-point worsening on any 1 of the individual MG-ADL
items, excluding ocular items), or health in jeopardy if rescue
therapy was not given, as determined by the treating physi-
cian. The exacerbation and hospitalization event rates were
compared with rates during the year before entering REGAIN
(collected at REGAIN baseline assessment); the rescue ther-
apy event rate was compared with the rate in the placebo
group during REGAIN.
The primary efﬁcacy endpoint was change in mean MG-ADL
total score from baseline over time. Changes from REGAIN and
open-label baselines were evaluated. Secondary efﬁcacy end-
points included changes from baseline in mean QMG, MGC,
and MG-QOL15 total scores over time and the proportions of
patients achieving clinically meaningful responses to eculizu-
mab, prospectively deﬁned as improvements from baseline of at
least 3 points in MG-ADL total score or at least 5 points in QMG
total score.28–30 Other efﬁcacy endpoints included MGFA postin-
terventional status, a disease-speciﬁc outcome measure that cap-
tures the physician’s global assessment of the patient’s clinical
status after initiation of MG treatment.31 The same neurologist
skilled in evaluating patients with MG assessed the MGFA postin-
terventional status throughout the study (at weeks 26 and
40 and then every 26 weeks until end of study/early termina-
tion) according to the following categories relative to baseline:
improved (a substantial decrease in clinical manifestations or in
MG medications), unchanged (no substantial change in clinical
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FIGURE 1. Study design. *Interim data are reported from the December 31, 2017 data cutoff point. †During the blinded induction phase
of the open-label study, patients received eculizumab (1,200 mg; 4 vials) at day 1 and week 2 and received placebo (4 vials) at weeks
1 and 3 (eculizumab/eculizumab group) or placebo (1 vial) plus eculizumab (900 mg; 3 vials) each week (placebo/eculizumab group).
‡Patients who withdrew or discontinued after receiving any amount of eculizumab were required to complete a safety follow-up visit
8 weeks after their last eculizumab dose. SOC, standard of care.
Long-Term Eculizumab in gMG MUSCLE & NERVE Month 2019 3
manifestations or reduction in MG medications), or worse
(a substantial increase in clinical manifestations or MG medica-
tions).31 Patients who had improved were also evaluated for
minimal manifestation and pharmacological remission status.31
Statistical Analysis. Safety analyses were performed for
all patients who received at least 1 dose of eculizumab in the
open-label study (safety set). Efﬁcacy analyses were conducted
by using the full analysis set, which comprised all patients who
received at least 1 dose of eculizumab in the open-label study
and had at least 1 postdose efﬁcacy assessment.
For exacerbations, hospitalizations, and rescue therapy use,
model-based event rates per 100 patient-years were calculated.
This was based on a generalized estimating equation Poisson
regression repeated-measures model with the number of events
as the dependent variable, the logarithm of patient-years as the
offset variable, and the study phase indicator (prestudy, placebo,
or eculizumab) as the factor assuming a compound symmetry
correlation structure.
Two baselines were used for the efﬁcacy analyses, REGAIN base-
line, deﬁned as assessment at day 1 in the REGAIN study; and
open-label baseline, deﬁned as the last available assessment before
ﬁrst eculizumab infusion (this was typically the day-1 assessment in
the open-label study; when the day-1 data were missing, the most
recent assessment from REGAIN was used as the open-label base-
line). Changes from baseline in MG-ADL, QMG, MGC, and MG-
QOL15 total scores at a particular visit were based on repeated-
measures models. Separate repeated-measures models were used
for the eculizumab/eculizumab and placebo/eculizumab groups
because patients in the eculizumab/eculizumab group had already
received 6 months of eculizumab in REGAIN. Assessing the
change from the open-label baseline allowed for evaluation of the
eculizumab treatment effect in the placebo/eculizumab arm and
the effect of continued, long-term treatment in the eculizumab/
eculizumab arm. The change from REGAIN baseline allowed for
an assessment of all changes from time of entry to REGAIN. Miss-
ing efﬁcacy endpoint assessments were not imputed.
The responder analyses measured the proportion of patients
with clinically meaningful improvements from REGAIN baseline.
The proportions of patients experiencing this improvement with
and without prior on-study rescue therapy were determined at
each visit for both groups. Exact (Clopper–Pearson) 95% conﬁ-
dence intervals (CIs) for the true proportions are presented.
Data are presented as least-squares means (changes from
open-label baseline) and 95% CIs. All statistical analyses were
performed in SAS version 9.4 (SAS Institute, Cary, North Caro-
lina). This study did not have a data monitoring committee.
RESULTS
In this interim analysis, 117 of the 118 patients
who completed REGAIN enrolled in the open-label
study (eculizumab/eculizumab, 56; placebo/eculizu-
mab, 61) and were included in the safety analysis,
and 116 patients were included in the efﬁcacy analy-
sis (eculizumab/eculizumab, 56; placebo/eculizumab,
60); approval for the inclusion of 1 patient in the
interim efﬁcacy analyses was not given by their national
health authority.
At the time of data cutoff, study participation was ongo-
ing for 73% of patients. Five patients (eculizumab/eculi-
zumab, 2; placebo/eculizumab, 3) had completed the
study. Among the 27 patients who discontinued the study,
6 patients discontinued because of 1 or more adverse
events, and 3 patients died. In addition, study investiga-
tors withdrew 5 patients, 12 patients withdrew consent,
and 1 patient discontinued for a reason described as
“other” (Fig. 2) after amedian period of eculizumab ther-
apy of 379 days because of various factors including ongo-
ing comorbidities, perceived lack of clinical beneﬁt, and
logistical problems with clinic attendance (Supp. Info.
Table 1).
Patient demographics for the study population were
reported for REGAIN.14 Patient characteristics were simi-
lar between the eculizumab/eculizumab and placebo/
eculizumab groups (Table 1). In total, 38 patients requir-
ed revaccination against N meningitidis (eculizumab/
eculizumab, 20; placebo/eculizumab, 18).
The median duration of eculizumab treatment for
all 117 patients during the open-label study was
22.7 months (range, 1 day to 37.3 months). Reported
data are based on 227 patient-years of open-label eculi-
zumab exposure at the time of data cutoff.
The most common adverse events were headache
and nasopharyngitis, which were experienced by 37.6%
and 31.6% of patients, respectively (Table 2). The most
common serious adverse event was MG worsening,
Assigned and received
eculizumab/eculizumab
(n = 56)
Assigned and received
placebo/eculizumab
(n = 61)
• Completed study (n = 2)
• Discontinued (n = 12) owing to:
 – Adverse event (n = 2)
 – Death (n = 2)
 – Physician decision (n = 3)
 – Withdrawal by patient (n = 4)
 – Other (n = 1)
Eculizmab/eculizumab
Placebo/eculizumab
• Completed study (n = 3)
• Discontinued (n = 15) owing to:
 – Adverse event (n = 4)
 – Death (n = 1)
 – Physician decision (n = 2)
 – Withdrawal by patient (n = 8)Continuing in study
(n = 42)
Continuing in study
(n = 43)
Enrolled
(N = 117)
FIGURE 2. Patient disposition through December 31, 2017. In total, 117 patients enrolled in the open-label study, of whom 56 had
received eculizumab and 61 had received placebo during REGAIN. As of December 31, 2017, twenty-seven patients had discontinued,
5 patients had completed the study, and 85 patients were continuing in the study.
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which occurred in 12.8% of patients (Table 2). Three
patients experienced a serious adverse event of MG cri-
sis, which resulted in study discontinuation for 2 of
them. Six patients withdrew from the study because of
a serious adverse event. All serious adverse events are
listed in Supporting Information Table 2.
At the time of this interim analysis, 3 deaths had
occurred. The death of 1 patient who was concomitantly
receiving azathioprine was attributed to hemophagocy-
tic lymphohistiocytosis associated with cytomegalovirus
infection of the liver resulting in multiple organ failure.
The second death was attributed to end-stage liver dis-
ease in a patient with cryptogenic liver cirrhosis and a
medical history of fatty liver, and the third death was
due to pulmonary embolism that occurred in a patient
who was in the hospital recovering from cardiogenic
shock secondary to sepsis complicated by deep vein
thrombosis.
During the open-label study, 22 (18.8%) patients
experienced an infectious event of special interest,
including 5 cases of sepsis, septic shock, or pseudo-
monas sepsis and 1 case each of aspergillus, cytomeg-
alovirus, and pseudomonas infection (Supp. Info.
Table 3). The proportion of patients experiencing
these infections or other adverse events of special
interest (infusion-related reactions, serious cutane-
ous reactions [urticaria], and cardiac disorders) was
in line with that observed during REGAIN. Similar
proportions of patients in the eculizumab/eculizumab
and placebo/eculizumab groups experienced these
adverse events, and rates did not change over time in
the open-label study (Supp. Info. Table 4). There were
no cases of meningococcal infection at the interim data
cutoff date; 1 case, which was resolved with antibiotic
treatment, occurred after this date.
In total, 59 MG exacerbations (including MG crises,
substantial symptomatic worsening, and health in jeop-
ardy if rescue therapy was not given) were experienced
by 29 patients during the open-label study before data
cutoff. Compared with the year before REGAIN start, the
exacerbation rate was reduced by 75.2% (prestudy, 102.4
exacerbations per 100 patient-years; open-label study,
25.4 exacerbations per 100 patient-years; P < 0.0001;
Table 1. Demographics and baseline characteristics of patients
entering the open-label study by treatment group (safety set)
Variable
Eculizumab/
eculizumab,
n = 56
Placebo/
eculizumab,
n = 61
All
patients,
N = 117
Mean age (SD),
y*
47.2 (15.5) 47.5 (17.9) 47.4 (16.7)
Sex, n (%)
Men 18 (32.1) 20 (32.8) 38 (32.5)
Women 38 (67.9) 41 (67.2) 79 (67.5)
Race, n (%)
Asian 3 (5.4) 16 (26.2) 19 (16.2)
Black 0 (0.0) 2 (3.3) 2 (1.7)
White 47 (83.9) 41 (67.2) 88 (75.2)
Multiple 1 (1.8) 0 (0.0) 1 (0.9)
Unknown 1 (1.8) 0 (0.0) 1 (0.9)
Other 4 (7.1) 2 (3.3) 6 (5.1)
MG duration,
mean (SD), y†
10.7 (7.9) 9.8 (8.5) 10.2 (8.2)
MG, myasthenia gravis; SD, standard deviation.
*On day 1 of the open-label extension study.
†Time from MG diagnosis to ﬁrst dose date in the open-label extension
study.
Table 2. Safety outcomes in all patients during the open-label
study
Event
Events,
n
Patients
experiencing an
event, n (%)
Events per
100 PY*
All adverse events 1,816 113 (96.6) 800.0
Most common adverse events†,‡, >10% of all patients, N = 117
Headache 71 44 (37.6) 31.3
Nasopharyngitis 76 37 (31.6) 33.5
Diarrhea 40 27 (23.1) 17.6
Upper respiratory
tract infection
55 27 (23.1) 24.2
Myasthenia gravis§ 40 23 (19.7) 17.6
Arthralgia 29 22 (18.8) 12.8
Nausea 26 21 (17.9) 11.5
Pain in extremity 21 18 (15.4) 9.3
Cough 21 17 (14.5) 9.3
Fatigue 21 17 (14.5) 9.3
Urinary tract
infection
32 17 (14.5) 14.1
Inﬂuenza 24 16 (13.7) 10.6
Gastroenteritis 15 14 (12.0) 6.6
Bronchitis 22 13 (11.1) 9.7
Pyrexia 17 13 (11.1) 7.5
Fall 24 12 (10.3) 10.6
All serious adverse
events
147 52 (44.4) 64.8
Most common (≥2 patients) MG- and infection-related serious adverse
events†,‡,k
Myasthenia gravis§ 28 15 (12.8) 12.3
Death 3 3 (2.6) 1.3
Myasthenia gravis
crisis
3 3 (2.6) 1.3
Pyrexia 3 3 (2.6) 1.3
Gastroenteritis 3 3 (2.6) 1.3
Pneumonia 3 3 (2.6) 1.3
Sepsis 3 3 (2.6) 1.3
Bronchitis 3 2 (1.7) 1.3
Inﬂuenza 2 2 (1.7) 0.9
Upper respiratory
tract infection
2 2 (1.7) 0.9
Urinary tract
infection
3 2 (1.7) 1.3
Aspiration
pneumonia
2 2 (1.7) 0.9
MedDRA, Medical Dictionary for Regulatory Activities; MG, myasthenia
gravis; PY, patient year.
*Patient-years is the sum of all years for all patients and observed event
rate is the number of events per PY multiplied by 100.
†When a patient had more than 1 adverse event for a particular preferred
term, that patient was counted only once for that preferred term.
‡MedDRA preferred term.
§Worsening (increased frequency and/or intensity) of a preexisting condi-
tion, including myasthenia gravis, is considered to be an adverse event.
kSerious adverse events are adverse events that are life-threatening or
result in death, hospitalization, or persistent or signiﬁcant disability or
incapacity, are congenital anomalies or birth defects, or are important
medical events. All serious adverse events in the open-label study are
listed in Supporting Information Table 1.
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Fig. 3). The exacerbation rate was also signiﬁcantly lower
than in the REGAIN placebo group (73.5 exacerbations
per 100 patient-years; P = 0.0061). The rate of rescue
therapy use was 23.1 events per 100 patient-years in the
open-label study, compared with 67.5 events per
100 patient-years in patients receiving placebo during
REGAIN (P = 0.0105; Fig. 3). The rate of MG-related
hospitalizations was reduced by over 80% compared with
the year before REGAIN start (prestudy, 81.3 hospitaliza-
tions per 100 patient-years; open-label study, 13.7 hospi-
talizations per 100 patient-years; P < 0.0001; Fig. 3). It
was also lower than in the REGAIN placebo group (48.4
hospitalizations per 100 patient-years; P = 0.0228; Fig. 3).
Improvements that had been demonstrated for
patients during 6 months of blinded eculizumab in
REGAIN were sustained during the open-label study
for a total maximum eculizumab treatment duration of
3 years (eculizumab/eculizumab group; Fig. 4). The
mean MG-ADL total score from open-label baseline did
not change signiﬁcantly in this group at each assess-
ment (−0.8 change from baseline to week 130 [n = 13];
P = 0.0990; Fig. 5A2). This sustained treatment effect
was also supported by similar ﬁndings with mean total
scores for QMG (0.1 change from baseline to week
130 [n = 13]; P = 0.8949; Fig. 5B2), MGC (−1.3 change
from baseline to week 130 [n = 13]; P = 0.1531;
Fig. 5C2), and MG-QOL15 (−1.2 change from baseline
to week 130 [n = 13]; P = 0.4756; Fig. 5D2).
Patients who had received placebo during REGAIN
experienced a rapid and signiﬁcant improvement when
they commenced eculizumab at the start of the open-
label extension (Fig. 5A1, B1, C1, D1). Improvements
from open-label baseline in mean MG-ADL total score as
well as QMG, MGC, and MG-QOL15 total scores were of
similar magnitude to those experienced by eculizumab-
treated patients in REGAIN. The mean change from
open-label baseline was statistically signiﬁcant as early as
the ﬁrst visit after eculizumab administration (assessed at
week 1 for MG-ADL [−1.6 from baseline], QMG [−2.3
from baseline], and MGC [−3.0 from baseline] and at
week 4 for MG-QOL15 [−5.4 from baseline]; all
P < 0.0001; Fig. 5A1, B1, C1, D1), with over half of the
improvement occurring in the ﬁrst 3 months. These
improvements were sustained over 30 months (mean
change in MG-ADL total score from open-label baseline
to month 30,−3.8; P < 0.0001; n = 15).
At the last assessment for this interim analysis,
55.2% of patients in the open-label study demon-
strated a clinically meaningful response in activities of
daily living (at least a 3-point improvement from
REGAIN baseline in MG-ADL total score without use
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FIGURE 4. Change from REGAIN baseline to week 130 in the open-label extension study in MG-ADL (A), QMG (B), MGC (C), and MG-
QOL15 (D) total scores (mean [95% CI]) by treatment arm over time (full analysis set). Patient numbers were not the same for each
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of rescue therapy). When analysis was performed
regardless of rescue therapy, 71.6% of patients experi-
enced this improvement. Over one-third (39.7%) of
patients experienced a clinically meaningful response
in muscle strength (at least a 5-point improvement
from REGAIN baseline in QMG total score without
rescue therapy use), and 48.3% experienced this
improvement regardless of rescue therapy use.
At the ﬁnal MGFA postinterventional status evalua-
tion before this data cutoff, 74.1% (86/116) of
patients were reported by their investigator to have
clinically improved compared with REGAIN baseline.
In addition, most (65/116 [56.0%]) patients were
deemed to have achieved minimal manifestations of
MG or pharmacological remission.
DISCUSSION
Inhibition of terminal complement activity with eculi-
zumab is a biologically rational approach to prevent dam-
age at the neuromuscular junction in patients with
AChR+ refractory gMG.22 Eculizumab has been reported
to produce rapid and clinically meaningful improve-
ments in activities of daily living, muscle strength, func-
tional ability, and quality of life and is well tolerated in
these patients.14 This interim analysis of the open-label
extension study provides evidence that the safety and efﬁ-
cacy of eculizumab in this patient population are sus-
tained with long-term treatment.
The safety data for eculizumab in this study are in
line with the current safety proﬁle in patients with
refractory gMG and with its well-characterized safety
proﬁle (on the basis of >10 years of postmarketing
experience) in the other approved indications, PNH
and aHUS.14,32–34 Consistent with the mode of action
of eculizumab, infections were the most commonly
reported events among the adverse events of special
interest. The prevalence of infections and other events
of special interest did not change with continued eculizu-
mab exposure. To mitigate the risk of meningococcal
infection, patients were required to receive meningococ-
cal vaccination as described in Materials and Methods.
There were no occurrences of meningococcal infection
by data cutoff; 1 nonfatal case after this date has been
reported. Three fatal events were reported in patients
with important comorbidities that likely contributed to
the clinical outcome.
The rapid response to eculizumab across multiple
disease-speciﬁc measures in patients who had previ-
ously received placebo conﬁrms the effect of eculizu-
mab recorded in REGAIN and exceeded the response
to placebo that was observed during REGAIN. The
maintenance of this effect in patients who received
eculizumab for up to 3 years provides evidence of
its durability. The open-label study not only sup-
ports and extends the body of evidence for the
treatment effect of eculizumab but also provides
new data regarding its positive impact on clinical
burden in patients who experience persistent MG
symptoms despite having a history of using multiple
ISTs. Among such patients, rates of potentially life-
threatening exacerbations,35 with consequent hos-
pitalizations and rescue therapy use, are typically
high.20 We have demonstrated that eculizumab
treatment signiﬁcantly reduces the rates of MG
exacerbations and MG-related hospitalizations in com-
parison with the last complete year before entering
the study and the rate of rescue therapy requirement
compared with placebo-treated patients in REGAIN.
In addition, most patients were reported by their phy-
sicians to have shown global clinical improvements
during the open-label study, and over half achieved
minimal manifestations status or pharmacological
remission according to MGFA postinterventional sta-
tus evaluation. These interim results add to the ﬁnd-
ings of REGAIN in providing evidence of the range of
clinical beneﬁts provided by eculizumab and the
impact it has on alleviating the burden of disease in
patients with previously refractory gMG.
These results add to the evidence that comple-
ment protein C5 inhibition is a relevant therapeutic
target in AChR+ refractory gMG and provide evi-
dence of the long-term beneﬁts of complement inhi-
bition by eculizumab for patients with this disease.
Additional investigations into the structural and
functional changes at the neuromuscular junction in
response to eculizumab that correlate with clinical
improvement in patients with MG may help to build
on the current preclinical evidence,36–38 fully charac-
terize the pathophysiology of MG including the role
of complement inhibition, and elucidate the mecha-
nism underlying the rapid response to eculizumab.
The main limitation of this study is the open-label
design, which could yield unconscious bias in reporting,
FIGURE 5 Change from open-label baseline in MG-ADL to week 4 (double-blind induction phase only; A1), MG-ADL to week 130
(A2), QMG to week 4 (B1), QMG to week 130 (B2), MGC to week 4 (C1), MGC to week 130 (C2), MG-QOL15 to week 4 (D1), and
MG-QOL15 to week 130 (D2); total scores (LS mean [95% CI]) by treatment group over time (full analysis set). Patient numbers were
not the same for each assessment. The stability of scores during the open-label study in the eculizumab/eculizumab group is evidence
of the maintenance of improvements achieved during eculizumab treatment in REGAIN in these patients. The rapid and signiﬁcant
improvements in the placebo/eculizumab group are evidence of these patients’ response to commencing eculizumab at the start of
the open-label study, including during the initial 4-week blinded induction phase. *P ≤ 0.05, †P ≤ 0.01, ‡P ≤ 0.0001 compared with
open-label baseline, repeated-measures analysis. BL, baseline; CI, conﬁdence interval; LS, least-squares; MG-ADL, Myasthenia
Gravis Activities of Daily Living; MGC, Myasthenia Gravis Composite scale; MG-QOL15, Myasthenia Gravis Quality of Life 15; QMG,
Quantitative Myasthenia Gravis scale.
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particularly of adverse events. The blinded induction
phase was designed to preserve the blinded nature of
REGAIN during the period of potential initial response.
Although the lack of a control group may also be con-
sidered a limitation, comparisons can be made with the
placebo group in REGAIN and with pre-REGAIN data
for the overall study population. Because over 90% of
REGAIN participants enrolled in the open-label exten-
sion study, selection bias based on inclusion in the
open-label study population is unlikely.
Future analyses of long-term eculizumab data,
including changes in IST and corticosteroid use dur-
ing eculizumab therapy; the time course of clinical
improvements; and achievement of minimal manifes-
tations will be important for understanding the role
of eculizumab in the treatment of individuals with
refractory gMG.
In conclusion, results of this interim analysis conﬁrm
the rapid and robust response to eculizumab that was
observed during REGAIN and support the long-term
clinical effectiveness and safety of eculizumab in patients
with AChR+ refractory gMG who previously experienced
persistent symptoms and signiﬁcant morbidities despite
concomitant IST. Improvements in activities of daily liv-
ing, muscle strength, functional ability, and quality of
life were maintained through 3 years in patients receiv-
ing eculizumab. This study also provides new evidence
for other clinical beneﬁts of eculizumab in these
patients, including reducing the frequency of disease
exacerbations. The completion of this open-label exten-
sion study will provide additional opportunities to con-
tinue studying and understanding the long-term
beneﬁts of eculizumab in patients with gMG.
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